Ritlecitinib is the first in a new class of oral highly selective kinase inhibitors.
CTP-543 is an investigational oral selective inhibitor of JAK1 and JAK2.
The THRIVE-AA1 trial included adults aged 18 to 65 years with moderate to severe alopecia areata who had at least 50% scalp hair loss.
Improvement in lesional scalp transcriptome toward nonlesional profile seen at week 24 for both ritlecitinib, brepocitinib
However, many patients experience improvements in hair density with standard alopecia treatments
Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.